Showing 2311-2320 of 19316 results for "".
Antiplatelet Therapy After Drug-Eluting Stent Implantation
https://reachmd.com/programs/heart-matters/antiplatelet-therapy-after-drug-eluting-stent-implantation/3959/It is no longer a question of whether antiplatelet therapy should be used following implantation of a drug-eluting stent, but rather to what extent and to what duration. With this in mind, many new challenges arise, from bleeding risks to drug intolerance and product cost. Host Dr. Doug Weaver welcoInvestigational Approaches to Structural and Valvular Heart Disease
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/investigational-approaches-to-structural-and-valvular-heart-disease/3442/We are increasingly able to turn to non-surgical therapies for structural and valvular heart disease. Host Dr. Lee Freedman discusses investigational, catheter-based treatment with Dr. Howard Herrmann, professor of medicine, and director of interventional cardiology and the Cardiac Catheterization LHelping Patients Deal with the Psychosocial Issues of Huntington's Disease
https://reachmd.com/programs/clinicians-roundtable/helping-patients-deal-with-the-psychosocial-issues-of-huntingtons-disease/3074/Dr. Robert Klitzman, associate professor of clinical psychology at Columbia University, discusses how to prepare patients and their families to deal with the complex issues that arise in families that have inherited Huntington's disease. Join host Dr. Maurice Pickard for this important discussion.Incorporating Spirituality into Medical Practice
https://reachmd.com/programs/clinicians-roundtable/incorporating-spirituality-into-medical-practice/2786/How can we address the formless notion of spirituality in the exam room? Moving beyond religion, Dr. Christina Puchalski, internist, and Director of the George Washington Institute for Spirituality in Health, and Associate Professor of Medicine and Health Sciences at George Washington University spePharma and Biotech Industries Pursue Treatments for Cardiac Inflammation
https://reachmd.com/programs/clinicians-roundtable/pharma-and-biotech-industries-pursue-treatments-for-cardiac-inflammation/3660/A treatment for atherosclerosis and the chronic inflammation in arterial blood vessels could be entering critical clinical trial stages that may result in a novel new treatment. Dr. Lawrence Cohen, president and chief executive officer of VIA Pharmaceuticals lays out for host ChiManaging Insulin-Resistant Patients With Multiple Risk Factors
https://reachmd.com/programs/lipid-luminations/managing-insulin-resistant-patients-with-multiple-risk-factors/3323/Host Dr. Larry Kaskel welcomes Dr. Yehuda Handelsman, medical director of the Metabolic Institute of America and chair of the International Committee for Insulin Resistance. Dr. Handelsman examines the relationship of insulin resistance to metabolic syndrome, as well as a series of clinical conditioThe ARBITER 6-HALTS Trial: Clinical Implications
https://reachmd.com/programs/heart-matters/the-arbiter-6-halts-trial-clinical-implications/4990/Previous trials, including the ENHANCE trial, have raised doubts about the clinical benefits of adding ezetimibe to high-dose statin therapy. The ARBITER 6-HALTS trial added further weight to the results of ENHANCE, wherein the ARBITER trial demonstrated that extended-release niacin was superior toMeasures to Improve Quality and Physician Payments
https://reachmd.com/programs/heart-matters/measures-to-improve-quality-and-physician-payments/3849/Host Dr. Jack Lewin speaks with Dr. James Dove, immediate past president of the American College of Cardiology, about strategies to improve the integration of quality into our healthcare system. No physician wants to fall short of providing the best care available, so it is imperative, Dr. Dove saysThe Importance of Non-HDL Cholesterol Testing
https://reachmd.com/programs/lipid-luminations/the-importance-of-non-hdl-cholesterol-testing/3705/Dr. Terry A. Jacobson explains to host Dr. Larry Kaskel the importance of non-HDL cholesterol reporting in lipid management. Dr. Jacobson describes additional lipid parameters that are emerging as valuable adjuncts to the standard panel, including measurements of apolipopprtoeins and LDL particle siPredictive Value of Lipid Biomarkers and Inflammatory Markers
https://reachmd.com/programs/lipid-luminations/predictive-value-of-lipid-biomarkers-and-inflammatory-markers/6296/Lipid Luminations host Dr. Alan Brown and his guest, Dr. Michael Davidson, discuss the predictive value of lipid biomarkers and inflammatory markers, particularly when compared with traditional risk factors, as well as the process of developing consensus on the use of novel risk factors. Brought to